Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Up 68.6% in July

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 87,153 shares, an increase of 68.6% from the July 15th total of 51,687 shares. Based on an average trading volume of 119,074 shares, the short-interest ratio is currently 0.7 days. Approximately 14.5% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several research firms have weighed in on JAGX. Weiss Ratings restated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Friday, July 17th. Wall Street Zen upgraded Jaguar Animal Health from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Jaguar Animal Health presently has an average rating of “Sell”.

Jaguar Animal Health Price Performance

Shares of Jaguar Animal Health stock traded down $0.04 during midday trading on Monday, reaching $0.88. The company had a trading volume of 120,398 shares, compared to its average volume of 105,603. The stock has a fifty day moving average price of $1.90 and a 200 day moving average price of $9.84. Jaguar Animal Health has a fifty-two week low of $0.72 and a fifty-two week high of $85.40. The firm has a market cap of $527,340.00, a PE ratio of -0.00 and a beta of -0.06.

Jaguar Animal Health (NASDAQ:JAGX) last released its earnings results on Wednesday, May 20th. The biotechnology company reported ($13.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($149.10) by $135.50. The firm had revenue of $20.27 million for the quarter, compared to analyst estimates of $4.21 million.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.